masthead

FOUNDATIONONE®

identifiserer behandlings- muligheter for de fleste pasienter med metastaserende eller tilbakevendende kreft med solide tumorer

Referanser
  1. Schwaederle M et al. Mol Cancer Ther 2015; 14:1488–1494.
  2. Frampton, G.M. et al. Nat Biotechnol 2013; 31:1023–1031.
  3. Roche Foundation Medicine Internal Information. 
  4. Drilon A et al. Clin Cancer Res 2015; 16:3631–3639.
  5. Rozenblum AB et al. J Thorac Oncol 2017; 2:258–268 (and supplementary material).
  6. FoundationOne technical information
  7. Genomeweb. Foundation Medicine Q3 revenues up 45 percent. Available at: https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-q3-revenues-45-percent [accessed November 2017].